Clinical TrialMay 21, 2026, 05:41 PM
Zentalis Azenosertib + Paclitaxel Achieves 50% ORR in Ovarian Cancer Trial
AI Summary
Zentalis Pharmaceuticals announced positive data from Part 1 of its Phase 1b MUIR trial, evaluating azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer (PROC). The combination demonstrated encouraging clinical activity with an overall response rate (ORR) of 39% and a median progression-free survival (PFS) of 7.3 months across all dose cohorts. Notably, the 250 mg intermittent dose cohort achieved a 50% ORR and 9.2-month median duration of response, along with a manageable safety profile. These results, which will be presented at ASCO 2026, support further evaluation of azenosertib-taxane combinations in ovarian cancer and other tumor types.
Key Highlights
- Azenosertib + paclitaxel achieved 39.1% ORR and 7.3-month median PFS in all-comer PROC (n=46).
- Optimal dose cohort (250 mg intermittent) showed 50.0% ORR and 9.2-month median DOR (n=12).
- Combination therapy demonstrated a manageable safety profile with low high-grade adverse events.
- Most frequent Grade ">="3 TRAEs were neutropenia (30.4%) and anemia (19.6%).
- Clinical activity was comparable in Cyclin E1-positive (41.4% ORR) and Cyclin E1-negative (35.7% ORR) patients.
- Results compare favorably to historical paclitaxel monotherapy (approx. 30% ORR, 4-month PFS).
Price Impact
More from ZNTL